目的 探讨噻托溴铵/奥达特罗对C、D组慢性阻塞性肺疾病（COPD）稳定期患者的临床治疗效果。方法 选取2021年1月—2021年10月期间本院收治的C、D 组COPD稳定期患者70例,按照随机数字表达均分为研究组（35例）和对照组（35例）。研究组给予噻托溴铵/奥达特罗雾化吸入治疗,对照组采取规律吸入布地奈德/福莫特罗粉治疗。均持续6个月治疗。比较2组一般资料、治疗前后肺功能指标、住院时间、mMRC评分、CAT评分、急性发作和糖皮质激素使用时间,以及不良反应。结果 治疗6个月后,研究组的肺功能指标包括第1秒用力呼气容积（FEV₁）、FEV1%预计值（FEV₁%pred）、用力肺活量（FVC）以及FEV₁/ FVC比值相比对照组均改善（均P< 0.05）。且相比对照组,研究组患者住院时间更短、治疗后mMRC评分和CAT评分更低、急性发作和糖皮质激素使用时间>30 d的例数更少（均P< 0.05）。此外,研究组患者治疗期间口干、恶心/呕吐、声音嘶哑和口腔感染的不良反应总发生率相比对照组更低。结论 噻托溴铵/奥达特罗能有效改善C、D 组COPD稳定期患者肺功能和临床症状,缩短住院时间和激素使用时间,减少急性发作和不良反应发生率,降低患者的治疗费用。

目的 了解遵义地区住院新生儿TORCH感染状况、发病率,为相关疾病的早期预防和治疗提供重要参考依据。方法 采用回顾性研究方法,对遵义市妇幼保健院2018—2019年住院新生儿弓形虫(TOX)、风疹(RV)、巨细胞(CMV)和单纯疱疹病毒(HSV)Ⅰ型感染结果进行分析。结果 遵义地区4 604例住院新生儿TORCH-IgM的总体阳性率为1.35%,其中CMV、TOX、RV、HSV Ⅰ的阳性率分别是1.00%、0.20%、0.13%和0.02%;对应TORCH-IgG的阳性率分别是67.38%、0.91%,54.54%、22.22%。对2018—2019年住院新生儿TORCH感染筛查结果显示:CMV-IgM阳性率分别从1.47%下降到0.43%(χ²=4.981,P=0.026),RV-IgM的阳性率从0.24%下降到0.00(χ²=12.446,P<0.001),差异均有统计学意义。在研究的2 607例男性患儿中,CMV、TOX、RV、HSV Ⅰ的IgM阳性率率分别是0.19%、0.11%、0.96%和0.04%,其IgG的阳性率为1.07%、55.20%、67.93%和22.48%。在研究的1 997例女性患儿中,CMV、TOX、RV、HSV Ⅰ的IgM阳性率分别是0.20%、0.15%、1.05%和0.00%,其IgG的阳性率为0.70%、53.68%、66.65%和21.88%。不同CMV-IgM感染对谷丙转氨酶(ALT)和谷草转氨酶(AST)的活性影响研究中,CMV-IgM抗体阳性对照组的ALT活性高于阴性组(t=-2.793,P<0.05),AST的活性无差异(t=0.067,P>0.05) 结论 遵义地区4 604例住院新生儿中以CMV感染率相对较高,不容忽视。2018—2019年CMV和RV的新近感染率呈下降趋势。CMV-IgM的感染能引起ALT活性的升高。

Objective To reveal the TORCH infection status and incidence of hospitalized newborns in Zunyi area, and provide important reference for early prevention and treatment of related diseases. Methods The retrospective research method was used to analyze the infection results of toxoplasma gondii (TOX), rubella virus (RV), cytomegalovirus (CMV) and herpes simplx virus (HSV) type I in hospitalized newborns in Zunyi Maternal and Child Health Hospital from 2018 to 2019. Results The overall positive rate of TORCH-IgM in 4 604 hospitalized newborns in Zunyi area was 1.35%, of which the positive rates of CMV, TOX, RV, and HSV Ⅰ were 1.00%, 0.20%, 0.13% and 0.02%, respectively; the corresponding TORCH-IgG positive rates were 67.38%, 0.91%, 54.54%, 22.22%. The TORCH infection screening results of neonates hospitalized in 2018—2019 showed that the CMV-IgM positive rate decreased from 1.47% to 0.43% (χ²=4.981, P=0.026), and the RV-IgM positive rate decreased from 0.24% to 0.00 (χ²=12.446, P< 0.001), the differences were statistically significant. In 2 607 male children, the IgM positive rates of CMV, TOX, RV and HSVⅠwere 0.19%, 0.11%, 0.96% and 0.04%, respectively; and the corresponding IgG positive rates were 1.07%, 55.20%, 67.93% and 22.48%. In 1 997 female children, the IgM positive rates of CMV, TOX, RV and HSVⅠwere 0.20%, 0.15%, 1.05% and 0.00,respectively; and the corresponding IgG positive rate was 0.70%, 53.68%, 66.65% and 21.88%. In the study of effects of different CMV-IgM infection on alanine aminotransferase(ALT) and aspartate aminotransferase(AST) activity, the ALT activity of CMV-IgM positive group was significantly higher than that of negative group (t=-2.793, P<0.05), and there was no difference in AST activity between the two groups (t=0.067, P>0.05). Conclusions The CMV infection rate among 4 604 hospitalized newborns in Zunyi area was relatively high, which should not be ignored. The recent infection rates of CMV and RV showed a downward trend from 2018 to 2019. CMV-IgM infection could cause an increase in ALT activity.